David Bell
Endocrinology, Diabetes & Metabolism · Irondale, ALNPI 1730230988
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $89,597 of the $111,897 with a category attached, or 80.1%. 20 manufacturers reported payments, led by Amarin Pharma, Inc. at 42.0% of the total. Reporting peaked in 2019 at $92,836 and has fallen 99.5% since, to $478 in 2025. Among endocrinology, diabetes & metabolism clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 167 payments — averaging $670.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$47K
- Novo Nordisk$26K
- AstraZeneca$16K
- Johnson & Johnson$10K
- Bayer$5K
- Kowa Pharmaceuticals America, Inc.$3K
- plus $6K from 14 others
What the payments were for
- Consulting fees$3,7483%
- Speaking & faculty fees$89,59780%
- Travel & lodging$12,05311%
- Food & beverage$6,3256%
- Education$1740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 62 | $46,994 |
| Novo Nordisk | 26 | $25,871 |
| AstraZeneca | 13 | $15,643 |
| Johnson & Johnson | 19 | $9,672 |
| Bayer | 6 | $4,976 |
| Kowa Pharmaceuticals America, Inc. | 3 | $3,230 |
| Esperion Therapeutics, Inc. | 7 | $2,481 |
| Janssen Scientific Affairs, LLC | 10 | $921 |
| Recordati_rare_diseases_inc. | 2 | $344 |
| Averitas Pharma Inc. | 3 | $298 |
| Mannkind Corporation | 2 | $295 |
| BD | 1 | $283 |
| Lilly USA, LLC | 3 | $267 |
| Boehringer Ingelheim | 3 | $222 |
| Merck | 2 | $134 |
| Novartis | 1 | $119 |
| Corcept Therapeutics | 1 | $90 |
| Xeris Pharmaceuticals, Inc. | 1 | $28 |
| Lifescan, Inc. | 1 | $15 |
| Boston Scientific | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$111,897 in reported general payments places this provider in the 90th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 89 | $116,879 |
| JardianceEmpagliflozin | 38 | $60,809 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $15,333 |
| InvokanaCanagliflozin | 18 | $13,346 |
| NexletolBempedoic Acid | 18 | $12,664 |
| Icosapent Ethyl | 18 | $12,155 |
| Colesevelam Hcl | 17 | $7,649 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $5,587 |
| Humalog Kwikpen U-100Insulin Lispro | 25 | $4,523 |
| SynthroidLevothyroxine Sodium | 19 | $2,434 |
| PremarinEstrogens, Conjugated | 11 | $2,107 |
| Telmisartan | 18 | $622 |
| Levothyroxine Sodium | 30 | $594 |
| Pioglitazone Hcl | 36 | $577 |
| Rosuvastatin Calcium | 44 | $535 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $25,871 | $116,87989 claims |
| Boehringer IngelheimJardiance | $222 | $60,80938 claims |
| Johnson & JohnsonInvokana | $9,672 | $13,34618 claims |
| Esperion Therapeutics, Inc.Nexletol | $2,481 | $12,66418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Irondale
- Neil SchaffnerOpelika$642K
- Ralph TeagueBirmingham$487K
- Bantwal BaligaOpelika$483K
- William GarveyBirmingham$421K
- Judson MenefeeFairhope$168K
- William DebellTuscaloosa$161K
- Edison GoncalvesBirmingham$142K
- Bethany JacksonFlorence$90K
- Dwain WoodeHuntsville$78K
- Fernando BrilBirmingham$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.